OCUL - Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Benzinga
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programming & Data Operations, Xiaopeng "Jeff" Cai, MS; (ii) its newly appointed Vice President, Head of Biostatistics, Zhongwen "Justin" Tang, Ph.D.; and (iii) eleven other newly hired employees. The awards were approved by the Compensation Committee of Ocular and were made as inducements material to each individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Cai's inducement awards were granted effective as of April 30, 2024, and Dr. Tang's inducement awards will be granted effective as of May 7, 2024. Each of Mr. Cai's and Dr. Tang's inducement awards consist of (i) a non-statutory stock option to purchase up to 90,000 shares of the Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on the effective date of grant, and (ii) a restricted stock unit award representing the right to receive 28,333 shares of Ocular's common stock. Each stock option has a ...